Clinical Research Directory
Browse clinical research sites, groups, and studies.
Comparison of the Efficacy of Saccharomyces Boulardii and Rifaximin in the Treatment of Small Intestinal Bacterial Overgrowth
Sponsor: Shandong University
Summary
This multicenter randomized controlled study aims to systematically evaluate the efficacy and safety of Saccharomyces boulardii sachets versus rifaximin in the treatment of small intestinal bacterial overgrowth (SIBO), with a focus on symptom relief and the impacts of anxiety-depressive factors on the treatment of abdominal distension and diarrhea in SIBO patients. The findings will offer a new non-antibiotic therapeutic option for SIBO, especially for patients with antibiotic resistance or those requiring long-term management, and lay a theoretical foundation for the clinical application of intestinal microecological regulators.
Official title: Comparison of the Efficacy of Saccharomyces Boulardii and Rifaximin in the Treatment of Abdominal Distension and Diarrhea Related to Small Intestinal Bacterial Overgrowth:a Non-inferiority Randomized Controlled Study
Key Details
Gender
All
Age Range
18 Years - 70 Years
Study Type
INTERVENTIONAL
Enrollment
222
Start Date
2026-09-10
Completion Date
2027-12-31
Last Updated
2026-09-15
Healthy Volunteers
No
Interventions
Saccharomyces boulardii sachets
0.5 g, orally, twice daily for 2 weeks
Rifaximin (Xifaxan)
0.4 g, orally, twice daily for 2 weeks
Locations (1)
Qilu Hospital of Shandong University
Jinan, Shandong, China